The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
What is the rationale for combination venetoclax+Kd treatment in patients with t(11;14) RRMM?
Featured:
Jonathan L. KaufmanDuring the 20th International Myeloma Society Annual Meeting 2023, the Multiple Myeloma Hub was pleased to speak to Jonathan L. Kaufman, Emory University School of Medicine, Atlanta, US. We asked, What is the rationale for combination venetoclax+Kd treatment in patients with t(11;14) relapsed/ refractory multiple myeloma (RRMM)?
What is the rationale for combination venetoclax+Kd treatment in patients with t(11;14) RRMM?
In this interview, Jonathan Kaufman discusses how the addition of venetoclax to combination carfilzomib + dexamethasone (Kd) can improve outcomes in patients with t(11;14). Kaufman highlights the influence of Kd on the sensitivity of myeloma cells to B-cell lymphoma 2 (BCL-2) inhibition, and how this can improve the potency of BCL-2 inhibitors such as venetoclax.